-
公开(公告)号:US11566032B2
公开(公告)日:2023-01-31
申请号:US17315258
申请日:2021-05-07
IPC分类号: A61K31/095 , C07C321/06 , C07F9/24 , A61P39/00 , A61K45/06 , C07D241/04 , C07D243/08 , C07D243/10 , C07D401/04 , C07D487/04 , C07F9/6574
摘要: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to The use of these compounds as radio— and chemo—protectors is also described.
-
公开(公告)号:US20220185785A1
公开(公告)日:2022-06-16
申请号:US17603260
申请日:2020-04-13
发明人: Darryl RIDEOUT , Seth LEDERMAN
IPC分类号: C07D257/04 , C07D403/12 , C07D403/10 , C07D285/135 , C07D275/06 , C07D213/81 , C07D249/06 , C07D307/68 , C07C237/42 , C07C311/51 , C07C317/44 , C07D333/38 , C07D231/56 , C07D211/34 , C07D213/52 , C07C233/80 , C07C259/10 , C07D213/75 , C07D237/20 , C07D401/14 , C07D487/04
摘要: Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.
-
公开(公告)号:US20230174562A1
公开(公告)日:2023-06-08
申请号:US17923831
申请日:2021-05-07
IPC分类号: C07F9/165 , A61K45/06 , A61P39/00 , A61K31/661 , C07D243/08 , A61K31/551 , C07D241/04 , A61K31/495 , C07D243/10 , C07D245/02 , A61K31/395 , C07D245/04 , C07D487/04 , A61K31/4985 , C07C53/18 , C07D241/38 , A61K31/498 , C07F9/6571 , A61K31/675 , C07C323/25 , A61K31/145
CPC分类号: C07F9/1651 , A61K45/06 , A61P39/00 , A61K31/661 , C07D243/08 , A61K31/551 , C07D241/04 , A61K31/495 , C07D243/10 , C07D245/02 , A61K31/5545 , C07D245/04 , C07D487/04 , A61K31/4985 , C07C53/18 , C07D241/38 , A61K31/498 , C07F9/657118 , A61K31/675 , C07C323/25 , A61K31/145 , C07B2200/13
摘要: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methy-lamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.
-
公开(公告)号:US11517557B2
公开(公告)日:2022-12-06
申请号:US16630832
申请日:2018-07-13
发明人: Seth Lederman , Darryl Rideout , Greg Sullivan
IPC分类号: A61K31/397 , C07C211/32 , C07D205/04 , A61K45/06 , A61K31/135
摘要: The present invention relates to cyclobenzaprine analogs and amitriptyline analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
-
5.
公开(公告)号:US20220130500A1
公开(公告)日:2022-04-28
申请号:US17508182
申请日:2021-10-22
发明人: Seth Lederman , Philip B. Stark , Ben Vaughn
摘要: Systems and methods for an analysis of clinical trial data using randomization tests that honors the randomized design of the clinical trial are provided herein. In particular, a non-parametric analyzer implementing randomization tests and associated methods for analyzing clinical data is provided. The non-parametric analyzer receives clinical trial data comprising a data structure containing data corresponding to subjects in the clinical trial, where the subjects have been organized into treatment groups, including at least one control group. The non-parametric analyzer generates multiple treatment allocations of the data structure by reorganizing, at random, the subjects along with corresponding data to generate further groups. In some embodiments, the non-parametric analyzer determines the statistical significance based on an overall probability and the multiple allocations of the data structure. The overall probability may be generated via a combination analysis for comparing test statistics between groups of the data structure and the multiple allocations.
-
公开(公告)号:US20210388011A1
公开(公告)日:2021-12-16
申请号:US17315258
申请日:2021-05-07
IPC分类号: C07F9/24 , C07F9/6574 , C07D241/04 , C07D243/08 , C07D243/10 , C07D401/04 , C07D487/04 , A61K45/06 , A61P39/00
摘要: The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.
-
7.
公开(公告)号:US20240165126A1
公开(公告)日:2024-05-23
申请号:US18282285
申请日:2022-03-15
发明人: Seth Lederman , Siobhan J. Fogarty
IPC分类号: A61K31/554 , A61K9/20 , A61K31/485
CPC分类号: A61K31/554 , A61K9/2054 , A61K31/485
摘要: A composition comprising tianeptine, pharmaceutically acceptable salts thereof or polymorphs of one or both and naloxone or a pharmaceutically acceptable salt thereof, methods of manufacturing the composition, and methods for preventing or treating major depressive disorder (MDD) or symptoms associated therewith comprising administering the composition to a subject in need or at risk thereof.
-
公开(公告)号:US11970554B2
公开(公告)日:2024-04-30
申请号:US16976912
申请日:2019-03-01
CPC分类号: C07K7/16 , A61K51/084 , G01N33/60
摘要: Disclosed are 13N-oxytocin molecules, methods of manufacture of 13N-oxytocin molecules and methods of use of 13N-oxytocin molecules in the determination of the distribution and kinetics of 13N-oxytocin molecules after craniofacial or other application methods.
-
公开(公告)号:US20240024256A1
公开(公告)日:2024-01-25
申请号:US18265525
申请日:2021-12-07
发明人: Seth Lederman , Gregory M. Sullivan
IPC分类号: A61K31/135 , A61P25/00 , A61K9/00
CPC分类号: A61K31/135 , A61P25/00 , A61K9/006
摘要: Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and/or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.
-
公开(公告)号:US20240009146A1
公开(公告)日:2024-01-11
申请号:US18037815
申请日:2021-11-19
发明人: Seth Lederman , Greg M. Sullivan
IPC分类号: A61K31/137
CPC分类号: A61K31/137
摘要: The present disclosure provides a method for treating alcohol use disorder (AUD) and associated symptoms to a subject in need thereof by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable salt comprises a cyclobenzaprine acid salt.
-
-
-
-
-
-
-
-
-